Transdermal Corp.

DUBLIN--( BUSINESS WIRE )--The "Transdermal Scopolamine: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Transdermal Scopolamine Market to Reach $528.5 Million by 2027 In the changed post COVID-19 business landscape, the global market for Transdermal Scopolamine estimated at US$368.7 Million in the year 2020, is projected to reach a revised size of US$528.5 Million by 2027, growing at a CAGR of 5.3% over the analysis period 2020-2027. The U.S. Market is Estimated at $108.7 Million, While China is Forecast to Grow at 4.9% CAGR The Transdermal Scopolamine market in the U.S. is estimated at US$108.7 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$93.2 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR. Select Competitors (Total 41 Featured) - Alchem International Alkaloids of Australia ALZA Corporation Baxter International Inc. Caleb Pharmaceuticals Inc Centroflora-Cms Fine Chemicals Corporation GlaxoSmithKline Plc Myungmoon Pharma Co. Ltd. Novartis AG Perrigo Co. Plc Phytex Australia Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Transdermal Scopolamine - Global Key Competitors Percentage Market Share in 2022 (E) Impact of Covid-19 and a Looming Global Recession Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITION Companies Mentioned Alchem International Alkaloids of Australia ALZA Corporation Baxter International Inc. Caleb Pharmaceuticals Inc Centroflora-Cms Fine Chemicals Corporation GlaxoSmithKline Plc Myungmoon Pharma Co. Ltd. Novartis AG Perrigo Co. Plc Phytex Australia For more information about this report visit https://www.researchandmarkets.com/r/mjl3iv

DUBLIN, June 14, 2022 /PRNewswire/ -- The "Analgesics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. The global analgesics market reached a value of US$ 49.02 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 64.59 Billion by 2027, exhibiting a CAGR of 4.5% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor. Analgesics, also known as painkillers or pain relievers, are drugs that help in relieving pain without affecting consciousness, altering sensory perception, or blocking nerve impulse conduction. These drugs include paracetamol (known as acetaminophen or simply APAP in North America), nonsteroidal anti-inflammatory drugs (NSAIDs) such as the salicylates, and opioid drugs such as morphine and oxycodone. Analgesics are used for treating pain resulting from physiological injuries, surgeries, phantom aches, inflammation, neuropathic conditions and cancer treatments. Nowadays, rising internet penetration has enabled various e-commerce platforms to collaborate with pharmaceutical manufacturers to deliver drugs like analgesics at the doorstep of consumers. The primary factor catalyzing the demand for analgesics is the increasing geriatric population. In 2017, between 950-1000 million people were over the age of 60. However, by 2050, these numbers are expected to reach 2100 million, accounting for around 21% of the total global population. As older adults are more vulnerable to chronic and lifestyles diseases, it will significantly contribute to the sales of analgesics. Apart from this, many leading pharmaceutical companies are continually focusing on clinical advancements in both the delivery and design of analgesic drugs. They are also developing safer opioids with improved side effect profiles and effective pain relief. Moreover, the presence of a strong drug pipeline with efficacious drugs waiting for approvals by the United States Food and Drug Administration (USFDA) is further expected to enhance the use of analgesics across the globe. Competitive Landscape: The market has also been examined with the presence of numerous small and large manufacturers who compete in terms of prices and quality. Some of the leading players are: Bayer AG Novartis International AG GlaxoSmithKline PLC Pfizer Inc. Johnson & Johnson Pvt. Ltd. Reckitt Benckiser (RB) Group PLC Endo Pharmaceuticals PLC Bristol-Myers Squibb Company Eli Lilly and Company Sanofi SA Key Questions Answered in this Report: How has the global analgesics market performed so far and how will it perform in the coming years? What are the key regional markets? What has been the impact of COVID-19 on the global analgesics market? What is the breakup of the market on the basis of type? What is the breakup of the market on the basis of drug class? What is the breakup of the market on the basis of route of administration? What is the breakup of the market on the basis of pain type? What is the breakup of the market on the basis of application? What are the various stages in the value chain of the global analgesics market? What are the key driving factors and challenges in the global analgesics market? What is the structure of the global analgesics market and who are the key players? What is the degree of competition in the global analgesics market? Key Topics Covered: 1 Preface 2 Scope and Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Analgesics Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Breakup by Type 5.5 Market Breakup by Drug Class 5.6 Market Breakup by Route of Administration 5.7 Market Breakup by Pain Type 5.8 Market Breakup by Application 5.9 Market Breakup by Region 5.10 Market Forecast 6 Market Breakup by Type 6.1 Prescription 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Over the counter (OTC) 6.2.1 Market Trends 6.2.2 Market Forecast 7 Market Breakup by Drug Class 7.1 Opioids 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 NSAID 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Others 7.3.1 Market Trends 7.3.2 Market Forecast 8 Market Breakup by Route of Administration 8.1 Oral 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Parenteral 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Topical 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Transdermal 8.4.1 Market Trends 8.4.2 Market Forecast 8.5 Rectal 8.5.1 Market Trends 8.5.2 Market Forecast 9 Market Breakup by Pain Type 9.1 Musculoskeletal 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Surgical and Trauma 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Cancer 9.3.1 Market Trends 9.3.2 Market Forecast 9.4 Neuropathic 9.4.1 Market Trends 9.4.2 Market Forecast 9.5 Migraine 9.5.1 Market Trends 9.5.2 Market Forecast 9.6 Obstetrical 9.6.1 Market Trends 9.6.2 Market Forecast 9.7 Fibromyalgia 9.7.1 Market Trends 9.7.2 Market Forecast 9.8 Pain due to Burns 9.8.1 Market Trends 9.8.2 Market Forecast 9.9 Dental/Facial 9.9.1 Market Trends 9.9.2 Market Forecast 9.10 Pediatric 9.10.1 Market Trends 9.10.2 Market Forecast 9.11 Others 9.11.1 Market Trends 9.11.2 Market Forecast 10 Market Breakup by Application 10.1 Internal 10.1.1 Market Trends 10.1.2 Market Forecast 10.2 External 10.2.1 Market Trends 10.2.2 Market Forecast 11 Market Breakup by Region 12 Global Analgesics Industry: SWOT Analysis 13 Global Analgesics Industry: Value Chain Analysis 14 Global Analgesics Industry: Porters Five Forces Analysis 15 Global Analgesics Industry: Price Analysis 15.1 Price Indicators 15.2 Price Structure 15.3 Margin Analysis 16 Competitive Landscape 16.1 Market Structure 16.2 Key Players 16.3 Profiles of Key Players 16.3.1 Bayer AG 16.3.2 Novartis International AG 16.3.3 GlaxoSmithKline PLC 16.3.4 Pfizer Inc. 16.3.5 Johnson & Johnson Pvt. Ltd. 16.3.6 Reckitt Benckiser (RB) Group PLC 16.3.7 Endo Pharmaceuticals PLC 16.3.8 Bristol-Myers Squibb Company 16.3.9 Eli Lilly and Company 16.3.10 Sanofi SA For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets

PARAMUS, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary transdermal technology, today announced that it has developed several formulations to successfully deliver lenalidomide across the skin. With this milestone, Starton has advanced multiple formulation candidates in its transdermal lenalidomide (STAR-LLD) program into nonclinical studies. STAR-LLD is a proprietary, medicated, adhesive patch placed on the skin to deliver lenalidomide continuously at the optimal dose using up to 90% less drug when compared to approved oral formulations. “Oral lenalidomide has provided patients with multiple myeloma a life-changing therapy; however, many patients struggle with long-term tolerance which comes with a multitude of side effects,” said Mohamad Hussein, MD, Starton Board Member/Scientific Advisor, currently professor of medicine and oncology at University of South Florida and former Global Lead of Multiple Myeloma at Celgene (2008-2019). “I think STAR-LLD will be the second coming of lenalidomide by avoiding the cycle of high and low drug levels caused by short half life of oral administration, while increasing efficacy with fewer side effects.” Each formulation candidate uses proprietary technology to enhance its solubility, stability, and permeability – provisional patent applications have been filed. The invention includes a unique Method of Use with a pretreatment to modulate the outermost layer of the skin reversibly and facilitate drug uptake. “By overcoming the limits of how lenalidomide is dosed, we will potentially be able to help more people with multiple myeloma to benefit from this globally successful treatment in addition to those with chronic lymphocytic leukemia (CLL),” said Asher Chanan-Khan, MD, Starton Board Member/Scientific Advisor and Co-Chairman Hematologic Malignancies Program, Mayo Clinic Cancer Center. “Dose-related side effects previously limited the success of oral lenalidomide formulations despite showing efficacy in CLL. STAR-LLD is likely to become the first immunomodulatory drug (IMiD) to treat this blood cancer and a potential breakthrough for patients by becoming the first maintenance therapy to help people stay in remission.” Using a 505(b)(2) approval path, Starton is not anticipating to have to repeat nonclinical safety studies. Once target blood levels and skin tolerability are demonstrated, Starton will select a lead candidate to advance into human clinical trials. About STAR-LLD STAR-LLD is in development to expand the standard of care for the most common and rarely curable blood cancers, CLL and MM. A preclinical proof-of-concept study for STAR-LLD demonstrated that MM tumors caused by human myeloma cells grew 25-fold if untreated, five-fold when treated with oral lenalidomide and shrank by 80% with STAR-LLD. High-risk smoldering multiple myeloma (SMM) is also a target indication for STAR-LLD after a randomized trial showed that 40% with SMM treated with oral lenalidomide discontinued due to drug-related side effects, despite 91% achieving three-year progression-free survival versus the 66% who were monitored without receiving active treatment (the current standard of care) (Lonial 2020). In addition to a transdermal formulation, STAR-LLD is also in development as a continuous subcutaneous (SC) infusion of lenalidomide parenteral solution via an infusion pump. STAR-LLD SC is expected to enter clinical studies in Q4-2021. Starton has completed a pre-IND meeting for STAR-LLD SC and its final IND-enabling study is currently underway. Starton expects to reference prior findings of nonclinical safety for key sections of the New Drug Application (NDA) for REVLIMID. About Starton Therapeutics A clinical-stage biotechnology company focused on transforming standard of care therapies with proprietary transdermal technology, so people with cancer can receive continuous treatment to live better, longer. Starton’s proprietary transdermal technology is intended to increase efficacy of approved drugs, to make them more tolerable and expand their potential use. To learn more, visit . This press release contains forward-looking statements that are subject to risks and uncertainties. These forward-looking statements include information about possible or assumed future results of the Company’s business, financial condition, liquidity, results of operations, plans and objectives. In some cases, you may identify forward-looking statements by words such as "may," "should," "plan," "intend," "potential," "continue," "believe," "expect," "predict," "anticipate" and "estimate," the negative of these words or other comparable words. These statements are only predictions. One should not place undue reliance on these forward-looking statements. The forward-looking statements are qualified by their terms and/or important factors, many of which are outside the Company's control and involve a number of risks, uncertainties and other factors that could cause actual results and events to differ materially from the statements made. The forward-looking statements are based on the Company's beliefs, assumptions and expectations of future performance, taking into account information currently available to the Company. Neither the Company nor any other person assumes responsibility for the accuracy or completeness of these statements. Information in this press release will be updated only to the extent required under applicable laws. If a change occurs, the Company’s business, financial condition, liquidity, results of operations, plans and objectives may vary materially from those expressed in the aforementioned forward-looking statements. Starton Investor Relations: investors@startontx.com +1 551 287 6456